Related Experiment Videos
Chemotherapy of advanced soft-tissue sarcomas
1Division of Medicine, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA.
Seminars in Surgical Oncology
|January 1, 1988
Summary
Doxorubicin and dacarbazine (DTIC) show the highest response rates for soft-tissue sarcomas. Ifosfamide is effective as a single agent, but adding cyclophosphamide to doxorubicin does not improve outcomes.
Area of Science:
- Medical Oncology
- Clinical Pharmacology
Background:
- Soft-tissue sarcomas (STS) are rare cancers with limited treatment options.
- Doxorubicin and ifosfamide are established single agents for STS, demonstrating response rates of 20-35%.
Purpose of the Study:
- To evaluate the efficacy of different chemotherapy regimens in soft-tissue sarcomas.
- To compare the effectiveness of single agents versus combination therapies.
Main Methods:
- Review of randomized clinical trials comparing chemotherapy agents for soft-tissue sarcomas.
- Analysis of response rates and adverse events for doxorubicin, ifosfamide, dacarbazine (DTIC), and cyclophosphamide.
Main Results:
- Doxorubicin and DTIC combination therapy demonstrated superior response rates compared to single agents.
- Ifosfamide showed a higher response rate than cyclophosphamide with less myelosuppression.
- Adding cyclophosphamide to doxorubicin-based regimens did not yield significant benefits.
Conclusions:
- The combination of doxorubicin and DTIC is the most effective regimen for soft-tissue sarcomas currently.
- Further investigation is needed to determine the role of ifosfamide in combination therapy for STS.